These data suggest the tPA/plasmin system could act to reduce islet amyloid accumulation, and the increase in PAI-1 in type 2 diabetes could inhibit a physiological protective effect of the fibrinolytic system in the islet. Here, PLG is linked to type 2 diabetes mellitus.